通讯作者: 姚锦, kmyaojin@163.com

DOI：10.12201/bmr.202603.00011

The expression of IL-16 in immune and tumor related diseases and its anti-tumor application research

• 摘要：白细胞介素-16(IL-16)是一种淋巴细胞趋化因子,由前体蛋白经caspase-3切割后形成具有生物活性的同源四聚体,通过与CD4、CD9及CCR5等受体结合发挥生物学功能。IL-16主要由人体免疫系统细胞表达,在循环系统以及炎症、感染和癌症部位表达升高。其在免疫调节、炎症反应及肿瘤微环境调控中发挥重要作用。IL-16在免疫细胞及多种非免疫细胞中均有表达,但表达水平及作用机制有明显差异,因此IL-16表达水平有希望成为疾病诊断和动态监测的指标；同时,IL-16基因的多态性与多种疾病的易感性相关,并且IL-16已被建议作为疾病预后预测的生物标志物之一。近年来,针对肿瘤靶向和免疫治疗策略的研究日益完善,IL-16作为新型药物靶点的候选者,IL-16相关抗体在多种疾病中表现出积极的治疗效果。本文系统综述了IL-16的生物学特征、表达分布、与多种疾病的关系及肿瘤治疗中的应用,旨在为炎症、免疫、肿瘤等相关疾病的诊断、治疗和预后预测提供参考。

  关键词： IL-16; 细胞因子; 肿瘤微环境; 免疫调节; 靶向治疗; 生物标志物

   

  Abstract: Interleukin-16 (IL-16) is a lymphocyte chemoattractant that forms a biologically active homotetramer through cleavage of its precursor protein by caspase-3. It exerts its biological functions by binding to receptors such as CD4, CD9, and CCR5. Primarily expressed by cells of the human immune system, IL-16 exhibits elevated levels in the circulatory system as well as at sites of inflammation, infection, and cancer. It plays a significant role in immune regulation, inflammatory responses, and modulation of the tumor microenvironment. Although IL-16 is expressed in various immune and non-immune cells, its expression levels and mechanisms of action differ substantially across cell types, making IL-16 expression a promising indicator for disease diagnosis and dynamic monitoring. Furthermore, polymorphisms in the IL-16 gene are associated with susceptibility to multiple diseases, and IL-16 has been proposed as a biomarker for predicting disease prognosis. In recent years, research on tumor-targeted and immunotherapeutic strategies has become increasingly refined. As a candidate for novel drug targeting, IL-16-related antibodies have demonstrated positive therapeutic effects in various diseases. This article systematically reviews the biological characteristics, expression patterns, associations with multiple diseases, and applications in cancer therapy of IL-16, aiming to provide insights for the diagnosis, treatment, and prognostic assessment of inflammation-, immune-, and tumor-related disorders.

  Key words: IL-16; cytokine; tumor microenvironment; immunomodulation; targeted therapy; biomarkers

  提交时间：2026-03-06

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 龚悦, 吴欢, 骆玉霜. 循环肿瘤细胞HER-2表达在胃腺癌靶向治疗中的应用. 2024. doi: 10.12201/bmr.202408.00001

  翁文辉, 方瑞, 张开茂. 鱼骨图分析法应用于抗肿瘤药物配置效果. 2024. doi: 10.12201/bmr.202408.00025

  雷亚典, 王海燕. 肿瘤免疫微环境影响T细胞的功能：聚焦ICB的局限性和联合治疗方案. 2024. doi: 10.12201/bmr.202412.00083

  支传瑞, 唐健, 于戈. 靶向肿瘤微环境代谢重编程：克服非小细胞肺癌治疗耐受的新策略. 2026. doi: 10.12201/bmr.202603.00010

  张迎欣, 刘汝洋, 张国鹏, 孙洪唯, 房振胜. IL-37在呼吸系统疾病中的研究进展. 2025. doi: 10.12201/bmr.202501.00038

  刘亚茹, 石浩, 孙冠群, 董静静, 叶寒锋, 郑乐一, 苏丹. 肿瘤患者免疫治疗后智能远程管理系统设计研究. 2022. doi: 10.12201/bmr.202206.00007

  周晶, 蒋莎莉. SLPI在宫颈腺癌的表达及其与HPV感染相关性研究. 2025. doi: 10.12201/bmr.202505.00012

  张昊天, 刘雪, 李淑菊. 急性肾损伤生物标志物的相关研究进展. 2025. doi: 10.12201/bmr.202508.00028

  王子婕, 张鑫众. 叶酸受体阳性循环肿瘤细胞与非小细胞肺癌发生发展的研究进展. 2025. doi: 10.12201/bmr.202506.00024

  汪满满, 杭于洁, 陈坤, 刘千羽, 章钰斌, 许亮, 张立雪, 白静雅▲. 肾脏纤维化生物标志物的研究进展. 2024. doi: 10.12201/bmr.202411.00072

• 序号	提交日期	编号	操作
  1	2026-01-30	10.12201/bmr.202603.00011V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论